Following encouraging ESMO data presentation, Artios will initiate a randomized Phase 2 study for potential first-in-class Polθ inhibitor, ART6043, in breast cancer
Financing co-led by SV Health and new investor, RA Capital Management, with participation from new investor Janus Henderson Investors alongside existing investors
CAMBRIDGE, United Kingdom and NEW YORK, November 17, 2025 – Artios Pharma Limited ("Artios"), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response ("DDR") in cancer, today announced the successful close of an oversubscribed $115 million Series D financing. The round was co-led by founding investor SV Health Investors and new investor RA Capital Management, with participation from new investor Janus Henderson Investors and broad support from Artios' existing investors.
The Series D proceeds will expand the clinical evaluation of Artios' lead program, alnodesertib, to enroll additional ATM-negative1 patients in each of second-line pancreatic cancer and third-line colorectal cancer, for which the program was recently granted U.S. FDA Fast Track Designation. At the AACR meeting in April 2025, Artios reported that alnodesertib, in combination with low-dose irinotecan, demonstrated a 50% confirmed overall response rate in patients with ATM-negative solid tumors at the recommended Phase 2 dose in the STELLA Phase 1/2a trial. There are currently no approved therapies specifically for patients whose tumors harbor ATM-deficiency, a population where alnodesertib has demonstrated durable responses across eight different solid tumors.
The proceeds from the financing will also be used to initiate a Phase 2 randomized clinical trial for Artios' second potential first-in-class candidate, ART6043, in patients with BRCA-mutant HER2-negative breast cancer who are eligible to receive a PARP inhibitor. The DNA polymerase Theta (Polθ) inhibitor, ART6043, demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals in data from a Phase 1/2a study presented at the ESMO Congress in September 2025. ...
